摘要
血管内皮生长因子(VEGF)在肿瘤血管生成过程中起着关键作用,并已成为抗肿瘤治疗的重要靶点。贝伐单抗为重组人源化抗VEGF的单克隆抗体,其治疗肿瘤具有良好的效果。目前,FDA已批准贝伐单抗用于转移性结直肠癌、转移性乳腺癌、晚期非小细胞肺癌、转移性肾细胞癌的一线治疗。除此之外,贝伐单抗在肝癌、胃癌、食管癌等其他恶性肿瘤的应用也取得令人鼓舞的结果。现就贝伐单抗在多种恶性肿瘤中的临床应用作一综述。
Vascular endothelial growth factor （VEGF） plays a critical role in tumor angiogenesis and has become an important target for anticancer treatment. Bevacizumab, a recombinant humanized anti-VEGF monoclonal antibody, has proven beneficial to cancer therapy. Currently, Bevacizumab was approved by the Food and Drug Administration （FDA） for first-line treatment in metastatic colorectal cancer, metastatic breast cancer, advanced non-small cell lung cancer and metastatic renal cell carcinoma. In addition, there are some evidences for its challenging efficacy in treatment of other solid tumors, such as hepatocellular carcinoma, gastric cancer, esophageal cancer and so on. The current clinical application of bevacizumab in variety of malignancies are reviewed.
出处
《中国肿瘤》
CAS
2010年第8期534-539,共6页
China Cancer
关键词
贝伐单抗
血管内皮生长因子
靶向治疗
肿瘤
bevacizumab
vascular endothelial growth factor
targeted therapy
neoplasms
